<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267926</url>
  </required_header>
  <id_info>
    <org_study_id>NURB-022-19S</org_study_id>
    <secondary_id>4337</secondary_id>
    <nct_id>NCT04267926</nct_id>
  </id_info>
  <brief_title>MitoQ for Fatigue in Multiple Sclerosis (MS)</brief_title>
  <acronym>MitoQ</acronym>
  <official_title>MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MS patients who receive Oral mitoquinone
      (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's
      fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if
      MitoQ has a significant change in fatigue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment of subjects on hold due to COVID-19 pandemic

      MitoQ is a potent antioxidant dietary supplement with potentially significant
      immunomodulatory and anti-inflammatory properties. While the cause of MS related fatigue is
      uncertain, the investigators believe that mitochondria dysfunction and resultant neuronal
      energy depletion may be an important contributor to fatigue in MS.

      This clinical trial will evaluate the potential beneficial effects of MitoQ on MS fatigue. It
      will also explore the effects of MitoQ on cognitive function, quality of life and mood. If
      enrolled in the study, patients will take two capsules of the study drug or placebo at the
      same time every day for twelve weeks. There will be 4 study visits where the participant will
      undergo medical and nervous system examinations, questionnaires, and blood draws. Because it
      is a placebo-controlled trial, participants will have a 33% chance of receiving either
      placebo (inactive), 20mg of MitoQ, or 40mg of MitoQ. This will be a blinded randomized study,
      meaning neither the participant nor the investigator will know who received the placebo or
      study drug.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The subject and investigator will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Fatigue Inventory Scale (MFIS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>MFIS is a self -reported fatigue survey. Scale 0 - 84</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>SDMT measures cognitive function. Scale 0-110</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>EDSS measures neurological function. Scale 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck's Depression Inventory (BDI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>BDI is a self-reported questionnaire measuring depression. Scale 0-21</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg of MitoQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg of oral mitoquinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40mg of MitoQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40mg of Oral Mitoquinol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg MitoQ</intervention_name>
    <description>a third of subject will receive 20mg of oral MitoQ</description>
    <arm_group_label>20mg of MitoQ</arm_group_label>
    <other_name>Oral Mitoquinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subject will receive Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40mg of MitoQ</intervention_name>
    <description>a third of subjects will receive 40mg of MitoQ</description>
    <arm_group_label>40mg of MitoQ</arm_group_label>
    <other_name>Oral Mitoquinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MS (any clinical subtype) as diagnosed by the 2017 McDonald criteria

          -  EDSS score of 2 to 8

          -  complaint of fatigue that has been persistent for at least two months

          -  Modified Fatigue Impact Scale (MFIS) score of 38 or greater

        Exclusion Criteria:

          -  treatment with systemic glucocorticoids in the prior six weeks

          -  Beck Depression Inventory (BDI) &gt;31 or BDI-FS&gt;10 (severe depression)

          -  significant MS exacerbation in prior 30 days

          -  previous use of MitoQ or Coenzyme Q10 (CoQ10) within thirty days of screening
             appointment

          -  other significant health problem that might increase risk of patient experiencing
             Adverse Events (AEs), e.g.:

               -  active coronary heart disease

               -  liver disease

               -  pulmonary disease

               -  diabetes mellitus

          -  pregnancy or intending to become pregnant or breastfeeding

          -  unable to complete the self-report forms

          -  unable to give informed consent

          -  prisoners

          -  any condition which would make the patient in the opinion of the investigator
             unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijayshree Yadav, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Portland Health Care System, Portland, OR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison Fryman</last_name>
    <phone>(503) 220-8262</phone>
    <email>Allison.Fryman@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vijayshree Yadav, MBBS</last_name>
    <phone>(503) 220-8262</phone>
    <email>vijayshree.yadav@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Allison Fryman</last_name>
      <phone>503-220-8262</phone>
      <email>Allison.Fryman@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Vijayshree Yadav, MBBS</last_name>
      <phone>(503) 220-8262</phone>
      <email>vijayshree.yadav@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Vijayshree Yadav, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Mitochondrial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

